Enclosed herewith the Financial Result (Standalone & Consolidated) along with Limited Review Report for the Quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.5 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Daikaffil Chemicals India Ltd reported Q3 FY26 standalone revenue from operations of Rs. 146.81 lakhs, a sharp fall from Rs. 603.60 lakhs in the previous quarter (Q2 FY26) and Rs. 349.87 lakhs in Q3 FY25. For the nine months ended December 2025, total revenue stood at Rs. 1,138.10 lakhs. The company continued to post losses, with a standalone net loss of Rs. 33.72 lakhs in Q3 and Rs. 124.97 lakhs for the 9M period, translating to a basic EPS of Rs. (0.56) for the quarter and Rs. (2.08) for 9M. Consolidated results show a slightly wider Q3 loss of Rs. 37.50 lakhs and 9M loss of Rs. 128.75 lakhs. Auditor N V C & Associates LLP issued an unmodified (clean) limited review opinion. This is the first set of consolidated results, following the incorporation of a wholly-owned subsidiary, Mikusu Global Industries Limited, on August 22, 2025, which is yet to generate any revenue (Rs. NIL).
Continued quarterly losses combined with a steep sequential and year-on-year drop in revenue highlight persistent operational stress for shareholders. The new subsidiary has just begun operations and is not contributing revenue yet, so near-term growth visibility remains limited and the stock may remain under pressure until profitability and revenue stabilise.